Renal & Urology News18h
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Hosted on MSN1h
I-Mab pauses CD73 antibody development in pipeline reshuffle
Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...
The American Journal of Managed Care5d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
FiercePharma5d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Targeted Oncology11d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Targeted Oncology2d
The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...
Cancer Therapy Advisor7d
Opdivo Qvantig Approved to Treat Solid Tumor Malignancies
The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.
Managed Healthcare Executive9d
FDA Approves Subcutaneous Opdivo to Treat Solid Tumors
Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...
GlobalData on MSN8d
FDA approves BMS’ Opdivo Qvantig for solid tumour indications
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...
pharmaphorum8d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...
Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors
Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...